Revenio Group Oyj (CHIX:REG1VH) EBIT: €21.2 Mil (TTM As of Mar. 2026)


CHIX:REG1VH Revenio Group Oyj CHIX:REG1VH
80 GF Score
Price €16.47
GF Value €36.95
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Revenio Group Oyj EBIT?

Revenio Group Oyj CHIX:REG1VH 80 EBIT is €21.2 Mil as of Mar. 2026. GuruFocus rates CHIX:REG1VH with a GF Score™ of 80/100 and a GF Value™ of €36.95 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Revenio Group Oyj's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €2.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €21.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Revenio Group Oyj's annualized ROC % for the quarter that ended in Mar. 2026 was 6.17%. Revenio Group Oyj's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 73.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Revenio Group Oyj's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.10%.


Revenio Group Oyj  (CHIX:REG1Vh) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Revenio Group Oyj's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=9.2 * ( 1 - 24.24% )/( (114.992 + 111)/ 2 )
=6.96992/112.996
=6.17 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Revenio Group Oyj's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.2/( ( (7.186 + max(2.735, 0)) + (6.9 + max(8.3, 0)) )/ 2 )
=9.2/( ( 9.921 + 15.2 )/ 2 )
=9.2/12.5605
=73.25 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.679 + 10.831 + 1.31) - (9.412 + 0 + 10.673)
=2.735

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.8 + 11.3 + 0) - (15.8 + 0 + 5)
=8.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Revenio Group Oyj's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=21.2/347.620
=6.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj EBIT Related Terms


Revenio Group Oyj EBIT Historical Data

* Premium members only.

The historical data trend for Revenio Group Oyj's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revenio Group Oyj EBIT Chart

Revenio Group Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.32 29.32 26.11 25.31 23.22

Revenio Group Oyj Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.10 6.10 6.70 2.30

CHIX:REG1VH vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Revenio Group Oyj's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revenio Group Oyj EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Revenio Group Oyj's EV-to-EBIT falls into.


CHIX:REG1VH
80GF Score
Revenio Group Oyj CHIX:REG1VH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revenio Group Oyj EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €21.2 Mil mean?
Revenio Group Oyj (CHIX:REG1VH) has a EBIT of €21.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Revenio Group Oyj.
Is Revenio Group Oyj's EBIT too high?
Revenio Group Oyj's current EBIT is €21.2 Mil. Overall, Revenio Group Oyj has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's EBIT compare to ABT and SYK?
Revenio Group Oyj's EBIT of €21.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Revenio Group Oyj. Revenio Group Oyj's current EBIT is €21.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (CHIX:REG1VH) is currently considered Significantly Undervalued. The stock's GF Value™ is €36.95, compared to a current price of €16.47 — trading 55.4% below its estimated fair value. The current EBIT is €21.2 Mil. Revenio Group Oyj's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current EBIT is €21.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?

Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued. The current stock price of €16.47 is trading 55.4% below its estimated GF Value™ of €36.95. GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.

Key valuation signals for CHIX:REG1VH:

  • EBIT: €21.2 Mil
  • GF Value™: €36.95 vs. price of €16.47 (55.4% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Revenio Group Oyj Business Description

Address Harkahaankuja 7, Vantaa, FIN, 01730
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
80GF Score

Get the complete analysis for CHIX:REG1VH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.47
Price
€36.95
GF Value